Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
COMPOSITION
DEVIRY 2.5 mg Each tablet contains: Medroxyprogesterone Acetate U.S.P. - 2.5 mg (6-methyl-17 hydroxyprogesterone acetate) DEVIRY 10 mg Each tablet contains: Medroxyprogesterone Acetate U.S.P - 10 mg (6-methyl-17hydroxyprogesterone acetate)
DESCRIPTION
Medroxyprogesterone acetate (MPA) is a derivative of progesterone that is
active by the parenteral and oral routes of administration. It is a white to offwhite, odorless crystalline powder, stable in air, melting between 200 and 210C. It is freely soluble in chloroform, soluble in acetone and in dioxane, sparingly soluble in alcohol and in methanol, slightly soluble in ether, and
insoluble in water.
HIGHLIGHTS (USPs)
Structurally related to progesterone. Safe & effective. No effect on HDL-C levels. No androgenic activity.
CLINICAL PHARMACOLOGY
Dysfunctional Uterine Bleeding (DUB). Secondary Amenorrhea o o o For diagnostic evaluation of endogenous estrogen status. Secondary Amenorrhea with adequate estrogen. Secondary Amenorrhea with inadequate estrogen.
CONTRAINDICATIONS
Patients with undiagnosed vaginal bleeding. Pregnancy (especially during the 1st trimester). Patients with P/H/O of arterial damage. Liver dysfunction or disease.
Known sensitivity to medroxyprogesterone acetate or any of the inactive
ingredients.
as:
PRECAUTIONS
Use with caution in patients with cardiovascular, renal or hepatic impairment, diabetes mellitus, asthma, epilepsy and migraine, or any
Exercise caution in patients with P/H/O of mental depression. If jaundice develops, discontinue the drug
ADVERSE REACTIONS
DEVIRY range is generally well tolerated. However, may cause effects such
Gastrointestinal disturbances & change in appetite. Weight gain and/or fluid retention. Skin reactions, such as acne, melasma or chloasma. Mental depression, fatigue, drowsiness, fever, headache etc.
DEVIRY 10 mg
Continue to use
DEVIRY 10 mg
day of the cycle for next 2 cycles. b) Secondary Amenorrhea For diagnostic evaluation of endogenous estrogen status:
stopped and the patient re-evaluated. Secondary Amenorrhea with inadequate estrogen :
Conjugase (Conjugated estrogens 0.625 mg) on days 1 through 25 and DEVIRY 10 mg on days 16 through 25, followed by five days no
Treatment to be started 7 days before the anticipated date of menses. Deviry 10 mg twice daily till the postponement is desired. Higher dose required if treatment is started less than 7 days before the anticipated date